Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry

Inzinger, Martin; Heschl, Bettina; Weger, Wolfgang; Hofer, Angelika; Legat, Franz J.; Gruber‐Wackernagel, Alexandra; Tilz, Hemma; Salmhofer, Wolfgang; Quehenberger, Franz; Wolf, Peter

doi:10.1111/j.1365-2133.2011.10396.x

Cited by 53 publications

(52 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median age of the psoriasis and CSU patients was 51 (range 13-85) and 40 (7-78) years, respectively. Psoriasis characteristics, extracted from the PsoRA [9,10,11], were available from 72 patients and are depicted in Table 1. These patients had no psoriasis arthritis and were scheduled to receive classical topical inpatient dithranol treatment in combination with local steroids and/or UVB phototherapy [12,13].…”

Section: Resultsmentioning

confidence: 99%

The Prevalence of Periodontitis Is Increased in Psoriasis and Linked to Its Inverse Subtype

Painsi

Hirtenfelder²,

Lange‐Asschenfeldt³

et al. 2017

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Periodontitis and psoriasis are suggested to be co-occurring, chronic inflammatory conditions with overlapping characteristics. However, respective evidence is rare and data on risk factors of periodontitis in psoriasis patients are minimal. The aim of this study was to expand the evidence of psoriasis-associated periodontitis and establish a potential risk profile for periodontitis. In total, data from 209 exacerbated psoriasis patients were retrospectively analyzed on recordings of periodontitis and compared with those of 91 patients with chronic spontaneous urticaria (CSU). Analysis showed a significantly increased prevalence of periodontitis in psoriasis compared to CSU patients with an odds ratio of 3.76 (95% CI = 1.60-10.27, p = 0.001). Within the psoriatic subtypes, the presence of the inverse type (affecting intertriginous body areas) was strongly linked to periodontitis with an odds ratio of 5.11 (95% CI = 1.36-20.38, p = 0.006). These results are enlarging the evidence for psoriasis-associated periodontitis and identify a link between the inverse type of psoriasis and periodontitis.

show abstract

Section: Resultsmentioning

confidence: 99%

The Prevalence of Periodontitis Is Increased in Psoriasis and Linked to Its Inverse Subtype

Painsi

Hirtenfelder²,

Lange‐Asschenfeldt³

et al. 2017

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…Bunların dışında, PUVA ile daha az sayıda tedavi gerekli olduğu ve düzelme de daha uzun süre devam ettiği için (104), daha az sayıda seans ile yanıt elde edilmek istenen hastalarda veya dar bant UVB sonrası hızlı nüks olanlarda da PUVA birinci basamakta tercih edilebilir. PUVA'nın IL-10 pozitif regülatuvar T hücreleri indüklerken Th17 yolağını inhibe ettiği gösterilmiş ve bu etki mekanizmasının, PUVA'nın, inflamatuvar ve hiperproliferatif deri değişiklikleri üzerine olan hızlı ve uzun süreli etkisinden sorumlu olabileceği bildirilmiştir (105,106). PUVA'nın, biyolojik tedavilere benzer etki mekanizması, biyolojik tedavilerle karşılaştırabilir, hatta bazı biyolojik ajandan üstün olan etkinliğinin sebebi olabilir.…”

Section: Psoriasiste Fototerapiunclassified

“…haftada, adalimumab ile %56 ve %22, etanersept ile %39 ve %29, ustekinumab ile %67 ve %39, infliksimab ile %100 ve %71 olarak bulunmuştur (106).…”

Section: Psoriasiste Fototerapiunclassified

Current Approach to Phototherapy Applications in Dermatology Practice: Part 2. Phototherapy in Vitiligo, Mycosis Fungoides, Atopic Dermatitis, Sclerosing Diseases and Psoriasis

Gençosmanoğlu¹

2017

tdd

View full text Add to dashboard Cite

“…In addition, a retrospective study comparing the efficacy of psoralen plus ultraviolet A (PUVA) light versus etanercept found PUVA responses to be higher than those of etanercept (PASI 90: 69% and 29%, PASI 75: 86% and 39%, and PASI 50: 89% and 84% for PUVA and etanercept, respectively) 50. The limitations of this study include the number of patients (PUVA n=118 and etanercept n=38), the retrospective design, and treatment length (12 weeks for etanercept and treatment completion for PUVA).…”

Section: Etanercept Combination Treatment and Comparative Studiesmentioning

confidence: 99%

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Kivelevitch

Mansouri

Menter

2014

BTT

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis.

show abstract

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry

Abstract: Retrospective analysis of registry data revealed that the primary efficacy of PUVA was superior to that of certain biologics. Prospective head-to-head studies of PUVA and biologics are warranted to confirm these observations.

Cited by 53 publications

References 30 publications

The Prevalence of Periodontitis Is Increased in Psoriasis and Linked to Its Inverse Subtype

The Prevalence of Periodontitis Is Increased in Psoriasis and Linked to Its Inverse Subtype

Current Approach to Phototherapy Applications in Dermatology Practice: Part 2. Phototherapy in Vitiligo, Mycosis Fungoides, Atopic Dermatitis, Sclerosing Diseases and Psoriasis

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Contact Info

Product

Resources

About